Participate in Research at CU Anschutz

This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.

This study plans to learn more about if an investigational drug called zanzalintinib (XL092) in combination with nivolumab is effective in treating unresectable, locally advanced, or metastatic non-clear cell renal cell carcinoma compared with sunitinib alone among patients who have never received systemic anticancer treatment. “Investigational” means that the study drug has not been approved by the U.S. Food and Drug Administration (FDA). You are being asked to be in this research study because you have unresectable, locally advanced or metastatic non-clear cell renal cell carcinoma (nccRCC), that has not been previously treated with systemic anticancer treatment.